How many clinical trials are studying Mesna?

5 recruiting trials in our tracked data involve Mesna.

What conditions is Mesna being studied for?

In our tracked recruiting trials, Mesna is being studied in trials for Crohn's Disease, Adrenocortical Cancer, Carcinoma.

Mesna: clinical trials recruiting now

Q: Is Mesna FDA-approved?

Yes. According to the FDA drug label available through openFDA, Mesna is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Mesna appears in the FDA drug-label database. Marketed as MESNEX.

FDA-approved use

MESNEX is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. MESNEX is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. ( 1 ) Limitation of Use: MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. ( 1 )

FDA label via openFDA

Phase breakdown

Phase 1 4 Phase 2 4

Conditions being studied

Condition	Trials
Crohn's Disease	2
Adrenocortical Cancer	1
Carcinoma	1
Clear Cell Sarcoma	1
Crohn Disease	1
Desmoplastic Small Round Cell Tumor	1
Diffuse Sclerosis Systemic	1
Ewing Sarcoma	1
Germ Cell Cancer	1
Hematologic Neoplasms	1
Hepatoblastoma	1
Hypertension	1
Interstitial Lung Disease	1
Lung cancer	1
Malignant Peripheral Nerve Sheath Tumors	1

Recruiting trials involving Mesna

Autologous Stem Cell Transplantation for Crohn's Disease
NCT00692939 · Phase: Phase 1, Phase 2 · Ages: 10 Years to 60 Years · Sex: All (male and female) · 2 locations
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
NCT03630211 · Phase: Phase 2 · Ages: 8 Years to 60 Years · Sex: All (male and female) · 3 locations
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
NCT04897321 · Phase: Phase 1 · Ages: Up to 21 Years · Sex: All (male and female) · 1 location
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
NCT04959175 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 85 Years · Sex: All (male and female) · 2 locations
Stem Cell Transplantation in Crohn's Disease
NCT04224558 · Phase: Phase 1, Phase 2 · Ages: 13 Years to 28 Years · Sex: All (male and female) · 1 location

Common questions

Is Mesna FDA-approved?

Yes, marketed as MESNEX.

How many recruiting trials involve Mesna?

5 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.